News Release

Dengue vaccine efficacy and viral genetic diversity

Peer-Reviewed Publication

Proceedings of the National Academy of Sciences

A statistical analysis of data from two Phase 3 clinical trials of a dengue vaccine comprising more than 30,000 participants, ages 2-16, suggests that vaccine efficacy decreased with the degree of antigen amino acid mismatch between the vaccine and the circulating virus in children ages 2-8, but not in children ages 9-16, possibly because the vaccine elicited a broadly protective response in older children with prior virus exposure.

###

Article #17-14250: "Viral genetic diversity and protective efficacy of a tetravalent dengue vaccine in two phase 3 trials," by Michal Juraska et al.

MEDIA CONTACT: Peter B. Gilbert, Fred Hutchinson Cancer Research Center, Seattle, WA; tel: 206-667-7299; e-mail: pgilbert@scharp.org


Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.